Acadian Asset Management
LOGC

Acadian Asset Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Acadian Asset Management’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50,339
Closed -$13K – 1969
2022
Q3 		$13K Hold
50,339
– – ﹤0.01% 1629
2022
Q2 		$18K Hold
50,339
– – ﹤0.01% 1623
2022
Q1 		$32K Buy
+50,339
New +$55.2K ﹤0.01% 1517
2020
Q1 		– Sell
-2,074
Closed -$15K – 1989
2019
Q4 		$15K Buy
+2,074
New +$18.7K ﹤0.01% 1741

Acadian Asset Management's LOGC Position: Q4 2022 in Review

Acadian Asset Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 50,339 shares — an estimated $13K sold.

Acadian Asset Management first reported a position in LOGC in Q4 2019 and held it in 4 quarters. The position peaked at $32K in Q1 2022. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

  • Acadian Asset Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Acadian Asset Management sold 50,339 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $13K.
  • Acadian Asset Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • Acadian Asset Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $32K in Q1 2022.
  • 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Acadian Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.